Concomitant pharmacotherapy overcomes immunotherapy challenges in aggressive blood cancer
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. It is caused by mutations in a large number of genes acquired during a person’s lifetime. One of these genes, the tumor suppressor gene TP53, plays a key role. Normally, TP53 helps prevent the development of tumors. However, blood cancer patients with this mutated […]